$HCAT
Health Catalyst, Inc. Stock $hcat

$hcat Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000163642222000024 Filed on May 10, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$68.09M	$55.85M
YoY Change	21.92%	23.78%
Cost Of Revenue	$33.67M	$27.34M
YoY Change	23.16%	13.59%
Gross Profit	$34.42M	$28.51M
YoY Change	20.72%	35.44%
Gross Profit Margin	50.55%	51.05%
Selling, General & Admin	$29.64M	$30.67M
YoY Change	-3.34%	32.25%
% of Gross Profit	86.13%	107.56%
Research & Development	$17.15M	$14.35M
YoY Change	19.54%	9.6%
% of Gross Profit	49.83%	50.32%
Depreciation & Amortization	$2.300M	$700.0K
YoY Change	228.57%	0.0%
% of Gross Profit	6.68%	2.46%
Operating Expenses	$58.44M	$52.83M
YoY Change	10.63%	34.92%
Operating Profit	-$24.35M	-$24.32M
YoY Change	0.12%	34.31%
Interest Expense	-$1.631M	-$3.980M
YoY Change	-59.02%	541.94%
% of Operating Profit
Other Income/Expense, Net	-$31.00K	$20.00K
YoY Change	-255.0%	-300.0%
Pretax Income	-$26.01M	-$28.27M
YoY Change	-8.0%	50.93%
Income Tax	-$3.600M	$101.0K
% Of Pretax Income
Net Earnings	-$22.46M	-$28.37M
YoY Change	-20.84%	62.21%
Net Earnings / Revenue	-32.98%	-50.8%
Basic Earnings Per Share	-$0.42	-$0.65
Diluted Earnings Per Share	-$0.54	-$0.65
COMMON SHARES
Basic Shares Outstanding	53.01M shares	43.87M shares
Diluted Shares Outstanding	53.22M shares	43.87M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$425.4M	$266.4M
YoY Change	59.69%	30.21%
Cash & Equivalents	$198.4M	$132.6M
Short-Term Investments	$227.0M	$133.8M
Other Short-Term Assets	$14.45M	$12.40M
YoY Change	16.52%	25.25%
Inventory
Prepaid Expenses
Receivables	$42.63M	$45.91M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$482.5M	$324.7M
YoY Change	48.58%	29.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.89M	$18.65M
YoY Change	33.43%	373.07%
Goodwill	$180.3M	$107.8M
YoY Change	67.25%	485.38%
Intangibles	$112.2M	$91.84M
YoY Change	22.14%	189.23%
Long-Term Investments
YoY Change
Other Assets	$4.421M	$4.068M
YoY Change	8.68%	142.43%
Total Long-Term Assets	$342.4M	$246.5M
YoY Change	38.93%	318.48%
TOTAL ASSETS
Total Short-Term Assets	$482.5M	$324.7M
Total Long-Term Assets	$342.4M	$246.5M
Total Assets	$824.9M	$571.2M
YoY Change	44.41%	85.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.865M	$4.626M
YoY Change	26.78%	69.08%
Accrued Expenses	$23.61M	$15.40M
YoY Change	53.31%	69.23%
Deferred Revenue	$61.80M	$51.63M
YoY Change	19.69%	45.64%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$171.9M
YoY Change
Total Short-Term Liabilities	$92.65M	$259.4M
YoY Change	-64.29%	414.45%
LONG-TERM LIABILITIES
Long-Term Debt	$225.4M	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$115.0K	$2.230M
YoY Change	-94.84%	584.05%
Total Long-Term Liabilities	$225.5M	$2.230M
YoY Change	10012.65%	-95.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.65M	$259.4M
Total Long-Term Liabilities	$225.5M	$2.230M
Total Liabilities	$344.0M	$302.4M
YoY Change	13.77%	188.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$884.1M	-$754.0M
YoY Change	17.25%	20.04%
Common Stock	$53.00K	$44.00K
YoY Change	20.45%	15.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$480.9M	$268.8M
YoY Change
Total Liabilities & Shareholders Equity	$824.9M	$571.2M
YoY Change	44.41%	85.01%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$22.46M	-$28.37M
YoY Change	-20.84%	62.21%
Depreciation, Depletion And Amortization	$2.300M	$700.0K
YoY Change	228.57%	0.0%
Cash From Operating Activities	$1.158M	-$3.143M
YoY Change	-136.84%	-81.26%
INVESTING ACTIVITIES
Capital Expenditures	$356.0K	$5.882M
YoY Change	-93.95%	1274.3%
Acquisitions	$18.51M	$0.00
YoY Change		-100.0%
Other Investing Activities	$5.736M	$44.63M
YoY Change	-87.15%	-13.19%
Cash From Investing Activities	$1.656M	$37.38M
YoY Change	-95.57%	-25.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.388M	$6.446M
YoY Change	-62.95%	-32.76%
NET CHANGE
Cash From Operating Activities	$1.158M	-$3.143M
Cash From Investing Activities	$1.656M	$37.38M
Cash From Financing Activities	$2.388M	$6.446M
Net Change In Cash	$5.201M	$40.67M
YoY Change	-87.21%	-5.26%
FREE CASH FLOW
Cash From Operating Activities	$1.158M	-$3.143M
Capital Expenditures	$356.0K	$5.882M
Free Cash Flow	$802.0K	-$9.025M
YoY Change	-108.89%	-47.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001636422
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38993
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	HEALTH CATALYST, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3337483
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	10897 South River Front Parkway #300
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South Jordan
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84095
CY2022Q1	dei	City Area Code CityAreaCode	801
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	708-6800
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	20226000	USD
CY2022Q1	dei	Trading Symbol TradingSymbol	HCAT
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54185049	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198428000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193227000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	226991000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	251754000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42627000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48801000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14448000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14609000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	482494000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	508391000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24889000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23316000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	112169000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	104788000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20610000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21133000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	180336000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	169972000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4421000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4496000	USD
CY2022Q1	us-gaap	Assets Assets	824919000	USD
CY2021Q4	us-gaap	Assets Assets	832096000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5865000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4693000	USD
CY2021Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23725000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3384000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3425000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	61799000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	56632000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1379000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4576000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	92653000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	93051000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	225397000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	180942000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	631000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	929000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19699000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20244000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5515000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	14719000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	115000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	113000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	344010000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	309998000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53493683	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53493683	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52622080	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52622080	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1365197000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1400972000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-884078000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-263000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-878860000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-67000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	480909000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	522098000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	824919000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	832096000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68087000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55846000	USD
CY2022Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	33996000	USD
CY2021Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	27338000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20818000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15651000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17148000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14345000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8823000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15015000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11649000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7814000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	58438000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	52825000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24347000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24317000	USD
CY2022Q1	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	1662000	USD
CY2021Q1	hcat	Interest And Other Expense Net InterestAndOtherExpenseNet	3952000	USD
CY2022Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-26009000	USD
CY2021Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-28269000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3551000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	101000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22458000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-28370000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53007000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43870000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53215000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43870000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22458000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-28370000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-118000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-78000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-41000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22654000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28400000	USD
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1809000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18438000	USD
CY2022Q1	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	2306000	USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	522098000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2885000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22458000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-196000	USD
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	480909000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	276099000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6488000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13640000	USD
CY2021Q1	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	1009000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-28370000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-30000	USD
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	268836000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-22458000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-28370000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	18120000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	13510000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11649000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7814000	USD
CY2022Q1	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-819000	USD
CY2021Q1	hcat	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-965000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-398000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-417000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	374000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2870000	USD
CY2022Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	200000	USD
CY2021Q1	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	300000	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3598000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8424000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2156000	USD
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-49000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-34000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6019000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2090000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-437000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2173000	USD
CY2022Q1	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	-4812000	USD
CY2021Q1	hcat	Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities	-5352000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4106000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3745000	USD
CY2022Q1	hcat	Increase Decrease In Contingent Consideration Liability IncreaseDecreaseInContingentConsiderationLiability	-741000	USD
CY2021Q1	hcat	Increase Decrease In Contingent Consideration Liability IncreaseDecreaseInContingentConsiderationLiability	0	USD
CY2022Q1	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-882000	USD
CY2021Q1	hcat	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1083000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1158000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3143000	USD
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	80960000	USD
CY2021Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	53240000	USD
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	56719000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	8621000	USD
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	18509000	USD
CY2021Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2022Q1	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	3261000	USD
CY2021Q1	hcat	Capitalized Of Internal Use Software CapitalizedOfInternalUseSoftware	887000	USD
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	463000	USD
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	480000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	356000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5882000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1656000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	37376000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1809000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6488000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1509000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1349000	USD
CY2022Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	930000	USD
CY2021Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1391000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2388000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6446000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-6000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5201000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40673000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193227000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91954000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198428000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132627000	USD
CY2022Q1	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	2306000	USD
CY2021Q1	hcat	Noncash Or Part Noncash Acquisition Common Stock Issued For Settlement Of Contingent Consideration Liability NoncashOrPartNoncashAcquisitionCommonStockIssuedForSettlementOfContingentConsiderationLiability	1009000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2885000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	885000	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2022Q1	hcat	Capitalized Internal Use Software In Accounts Payable And Accrued Liabilities CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities	528000	USD
CY2021Q1	hcat	Capitalized Internal Use Software In Accounts Payable And Accrued Liabilities CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities	0	USD
CY2022Q1	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	318000	USD
CY2021Q1	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	130000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1816000	USD
CY2022Q1	hcat	Revenue From Subscriptions Contract Notice Required For Termination RevenueFromSubscriptionsContractNoticeRequiredForTermination	P90D
CY2022Q1	hcat	Revenue From Subscriptions Contract Allowed Termination Period RevenueFromSubscriptionsContractAllowedTerminationPeriod	P1Y
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, provisions for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software and other intangible assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could significantly differ from those estimates.</span></div>
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	700000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	800000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	62400000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	57600000	USD
CY2022Q1	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	1400000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	1400000	USD
CY2022Q1	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P12M
CY2022Q1	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	2700000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	3000000	USD
CY2022Q1	hcat	Commission Payment Estimated Benefit Period CommissionPaymentEstimatedBenefitPeriod	P4Y
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1600000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1800000	USD
CY2022Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2022Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1700000	USD
CY2021Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	900000	USD
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	1000000	USD
CY2021Q1	us-gaap	Advertising Expense AdvertisingExpense	400000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68087000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55846000	USD
CY2022Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	segment
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Goodwill Goodwill	180336000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	169972000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	191035000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	78866000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	112169000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	174305000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	69517000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	104788000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9300000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7100000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	38398000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34749000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13509000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11433000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24889000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23316000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	2300000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	700000	USD
CY2022Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	3700000	USD
CY2021Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	1000000	USD
CY2022Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1300000	USD
CY2021Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	300000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	409463000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	205000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	409258000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	429741000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	88000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	429653000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	us-gaap	Interest Receivable InterestReceivable	500000	USD
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	800000	USD
CY2022Q1	hcat	Fair Value Measurement Aggregate Intrinsic Value FairValueMeasurementAggregateIntrinsicValue	6900000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10330000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17430000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9896000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6295000	USD
CY2022Q1	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	20226000	USD
CY2021Q4	hcat	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23725000	USD
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	USD
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	USD
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	USD
CY2022Q1	us-gaap	Share Price SharePrice	26.13
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Shares Outstanding SharesOutstanding	53918541	shares
CY2022Q1	us-gaap	Shares Issued SharesIssued	53918541	shares
CY2021Q4	us-gaap	Shares Issued SharesIssued	52690019	shares
CY2021Q4	us-gaap	Shares Outstanding SharesOutstanding	52690019	shares
CY2022Q1	hcat	Stockholders Vote StockholdersVote	1	vote
CY2022Q1	us-gaap	Dividends Cash DividendsCash	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22458000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28370000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53006704	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43870288	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22458000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28370000	USD
CY2022Q1	hcat	Change In Fair Value Of Dilutive Shares Issuable As Contingent Consideration ChangeInFairValueOfDilutiveSharesIssuableAsContingentConsideration	-6104000	USD
CY2021Q1	hcat	Change In Fair Value Of Dilutive Shares Issuable As Contingent Consideration ChangeInFairValueOfDilutiveSharesIssuableAsContingentConsideration	0	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28562000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28370000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53006704	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43870288	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	208326	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53215030	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43870288	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14728515	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9889785	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18120000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13510000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18120000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13510000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2115484	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.45
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	153221	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.65
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2849	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	13.17
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1959414	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.43
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M12D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28798387	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1959414	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.43
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	28798387	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1389100	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.73
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M18D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	21393812	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	281418	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	40.53
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.137
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3600000	USD
CY2022Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3600000	USD
CY2022Q1	hcat	Contract With Customer Liability Revenue Recognized Percentage ContractWithCustomerLiabilityRevenueRecognizedPercentage	0.45
CY2021Q1	hcat	Contract With Customer Liability Revenue Recognized Percentage ContractWithCustomerLiabilityRevenueRecognizedPercentage	0.42
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	80200000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.80
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P24M
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68087000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55846000	USD
CY2022Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-26009000	USD
CY2021Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-28269000	USD

Files In Submission

Name	View Source	Status
0001636422-22-000024-index-headers.html	Edgar Link	pending
0001636422-22-000024-index.html	Edgar Link	pending
0001636422-22-000024.txt	Edgar Link	pending
0001636422-22-000024-xbrl.zip	Edgar Link	pending
exhibit311-q12022xcertific.htm	Edgar Link	pending
exhibit312-q12022xcertific.htm	Edgar Link	pending
exhibit321-q12022xcertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hcat-20220331.htm	Edgar Link	pending
hcat-20220331.xsd	Edgar Link	pending
hcat-20220331_cal.xml	Edgar Link	unprocessable
hcat-20220331_def.xml	Edgar Link	unprocessable
hcat-20220331_htm.xml	Edgar Link	completed
hcat-20220331_lab.xml	Edgar Link	unprocessable
hcat-20220331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCAT
Health Catalyst, Inc. Stock $hcat

2022 Q1 Form 10-Q Financial Statement

#000163642222000024 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCAT Health Catalyst, Inc. Stock $hcat

2022 Q1 Form 10-Q Financial Statement

#000163642222000024 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCAT
Health Catalyst, Inc. Stock $hcat